Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 715

1.

Testosterone boosts for treatment of castration resistant prostate cancer: an experimental implementation of intermittent androgen deprivation.

Thelen P, Heinrich E, Bremmer F, Trojan L, Strauss A.

Prostate. 2013 Nov;73(15):1699-709. doi: 10.1002/pros.22711. Epub 2013 Jul 19.

PMID:
23868789
2.

Growth Inhibition by Testosterone in an Androgen Receptor Splice Variant-Driven Prostate Cancer Model.

Nakata D, Nakayama K, Masaki T, Tanaka A, Kusaka M, Watanabe T.

Prostate. 2016 Dec;76(16):1536-1545. doi: 10.1002/pros.23238. Epub 2016 Jul 30.

PMID:
27473672
3.

Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth.

Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, Steiner MS, Miller DD, Dalton JT, Narayanan R.

Clin Cancer Res. 2013 Oct 15;19(20):5613-25. doi: 10.1158/1078-0432.CCR-13-1151. Epub 2013 Aug 30.

4.

Reduced expression of the androgen receptor by third generation of antisense shows antitumor activity in models of prostate cancer.

Zhang Y, Castaneda S, Dumble M, Wang M, Mileski M, Qu Z, Kim S, Shi V, Kraft P, Gao Y, Pak J, Sapra P, Bandaru R, Zhao H, Vessella RL, Horak ID, Greenberger LM.

Mol Cancer Ther. 2011 Dec;10(12):2309-19. doi: 10.1158/1535-7163.MCT-11-0329. Epub 2011 Oct 25.

5.

Castration induces up-regulation of intratumoral androgen biosynthesis and androgen receptor expression in an orthotopic VCaP human prostate cancer xenograft model.

Knuuttila M, Yatkin E, Kallio J, Savolainen S, Laajala TD, Aittokallio T, Oksala R, Häkkinen M, Keski-Rahkonen P, Auriola S, Poutanen M, Mäkelä S.

Am J Pathol. 2014 Aug;184(8):2163-73. doi: 10.1016/j.ajpath.2014.04.010. Epub 2014 Jun 17.

PMID:
24949550
6.

Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer.

Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, Su LC.

J Biomed Sci. 2011 Aug 23;18:63. doi: 10.1186/1423-0127-18-63. Review.

7.

Identification of EP4 as a potential target for the treatment of castration-resistant prostate cancer using a novel xenograft model.

Terada N, Shimizu Y, Kamba T, Inoue T, Maeno A, Kobayashi T, Nakamura E, Kamoto T, Kanaji T, Maruyama T, Mikami Y, Toda Y, Matsuoka T, Okuno Y, Tsujimoto G, Narumiya S, Ogawa O.

Cancer Res. 2010 Feb 15;70(4):1606-15. doi: 10.1158/0008-5472.CAN-09-2984. Epub 2010 Feb 9.

8.

Y-box binding protein-1 promotes castration-resistant prostate cancer growth via androgen receptor expression.

Shiota M, Takeuchi A, Song Y, Yokomizo A, Kashiwagi E, Uchiumi T, Kuroiwa K, Tatsugami K, Fujimoto N, Oda Y, Naito S.

Endocr Relat Cancer. 2011 Jul 11;18(4):505-17. doi: 10.1530/ERC-11-0017. Print 2011 Aug.

9.

Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer.

Yu Z, Chen S, Sowalsky AG, Voznesensky OS, Mostaghel EA, Nelson PS, Cai C, Balk SP.

Clin Cancer Res. 2014 Mar 15;20(6):1590-600. doi: 10.1158/1078-0432.CCR-13-1863. Epub 2014 Jan 21.

10.

Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants.

Jernberg E, Thysell E, Bovinder Ylitalo E, Rudolfsson S, Crnalic S, Widmark A, Bergh A, Wikström P.

PLoS One. 2013 Nov 7;8(11):e77407. doi: 10.1371/journal.pone.0077407. eCollection 2013.

11.

Oxidative stress and androgen receptor signaling in the development and progression of castration-resistant prostate cancer.

Shiota M, Yokomizo A, Naito S.

Free Radic Biol Med. 2011 Oct 1;51(7):1320-8. doi: 10.1016/j.freeradbiomed.2011.07.011. Epub 2011 Jul 23. Review.

PMID:
21820046
12.

Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.

Hu R, Lu C, Mostaghel EA, Yegnasubramanian S, Gurel M, Tannahill C, Edwards J, Isaacs WB, Nelson PS, Bluemn E, Plymate SR, Luo J.

Cancer Res. 2012 Jul 15;72(14):3457-62. doi: 10.1158/0008-5472.CAN-11-3892. Epub 2012 Jun 18.

13.

Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival.

Hörnberg E, Ylitalo EB, Crnalic S, Antti H, Stattin P, Widmark A, Bergh A, Wikström P.

PLoS One. 2011 Apr 28;6(4):e19059. doi: 10.1371/journal.pone.0019059.

14.

Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.

Zhang X, Morrissey C, Sun S, Ketchandji M, Nelson PS, True LD, Vakar-Lopez F, Vessella RL, Plymate SR.

PLoS One. 2011;6(11):e27970. doi: 10.1371/journal.pone.0027970. Epub 2011 Nov 17.

15.

Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.

Vis AN, Schröder FH.

BJU Int. 2009 Aug;104(4):438-48. doi: 10.1111/j.1464-410X.2009.08695.x. Epub 2009 Jun 24. Review.

16.

Nrdp1-mediated regulation of ErbB3 expression by the androgen receptor in androgen-dependent but not castrate-resistant prostate cancer cells.

Chen L, Siddiqui S, Bose S, Mooso B, Asuncion A, Bedolla RG, Vinall R, Tepper CG, Gandour-Edwards R, Shi X, Lu XH, Siddiqui J, Chinnaiyan AM, Mehra R, Devere White RW, Carraway KL 3rd, Ghosh PM.

Cancer Res. 2010 Jul 15;70(14):5994-6003. doi: 10.1158/0008-5472.CAN-09-4440. Epub 2010 Jun 29.

17.

Androgen receptor-dependent regulation of Bcl-xL expression: Implication in prostate cancer progression.

Sun A, Tang J, Hong Y, Song J, Terranova PF, Thrasher JB, Svojanovsky S, Wang HG, Li B.

Prostate. 2008 Mar 1;68(4):453-61. doi: 10.1002/pros.20723.

PMID:
18196538
18.

Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.

Watson PA, Chen YF, Balbas MD, Wongvipat J, Socci ND, Viale A, Kim K, Sawyers CL.

Proc Natl Acad Sci U S A. 2010 Sep 28;107(39):16759-65. doi: 10.1073/pnas.1012443107. Epub 2010 Sep 7.

19.

Androgen receptors in hormone-dependent and castration-resistant prostate cancer.

Shafi AA, Yen AE, Weigel NL.

Pharmacol Ther. 2013 Dec;140(3):223-38. doi: 10.1016/j.pharmthera.2013.07.003. Epub 2013 Jul 13. Review.

PMID:
23859952
20.

Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.

Shiota M, Takeuchi A, Yokomizo A, Kashiwagi E, Tatsugami K, Naito S.

J Urol. 2012 Jul;188(1):300-6. doi: 10.1016/j.juro.2012.02.2553. Epub 2012 May 16.

PMID:
22608750

Supplemental Content

Support Center